ALG-000184, Publications ALG-000184 Has Favorable Antiviral Effect & Safety in Untreated Asian/Non-Asian HBeAg-Negative CHB Subjects
ALG-000184, Publications ALG-000184 (100 mg) + ETV Leads to Stronger Antiviral Effects Compared to ETV Alone in HBeAg-Positive CHB
ALG-000184, Publications ALG-000184 (300 mg) ± Entecavir Results in Substantial HBV Antigen Declines in Untreated HBeAg-Positive Subjects with CHB
ALG-055009, Publications Pharmacodynamics of Multiple Ascending Oral Doses of ALG-055009, a THR β Agonist, in Hyperlipidemic Subjects
Publication, Publications Synthesis and evaluation of highly potent HBV capsid assembly modulators (CAMs)
ALG-000184, Publications Long-term Dosing with ALG-000184 in HBeAg Positive Subjects Results in Unprecedented Multi-log Reductions in HBV Markers Including HBsAg
Preclinical, Publications Class-A Cams Induce Cell Death Through HBV Core Protein Aggregation And Potentially Activate The Innate Immune Response
Preclinical, Publications Discovery of a Liver Targeted Oral PD-L1 Small Molecule Inhibitor for the Treatment of Chronic Hepatitis B and Liver Cancer
ALG-055009, Publications Nonclinical Efficacy, Pharmacokinetic/Pharmacodynamic (PK/PD), and Toxicology Profile of ALG-055009, a Novel and Potent Thyroid Hormone Receptor β Agonist, for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)
ALG-000184, Publications Preclinical Resistance Profile and Antiviral Activity of the Best-in-Class CAM-E ALG-001075, the Parent Compound of ALG-000184